Health Catalyst (NASDAQ:HCAT) Rating Reiterated by Cantor Fitzgerald

Health Catalyst (NASDAQ:HCAT)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a report issued on Friday, Benzinga reports. They currently have a $16.00 price objective on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 84.12% from the stock’s previous close.

A number of other research analysts also recently issued reports on HCAT. JPMorgan Chase & Co. increased their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Piper Sandler decreased their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Stephens decreased their price objective on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Finally, Evercore ISI decreased their price objective on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, July 9th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.42.

Health Catalyst Price Performance

Shares of Health Catalyst stock opened at $8.69 on Friday. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $11.41. The business has a 50-day moving average of $7.29 and a two-hundred day moving average of $6.91. The company has a market capitalization of $513.01 million, a P/E ratio of -4.70 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. During the same period in the prior year, the company earned ($0.21) earnings per share. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. On average, equities analysts anticipate that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Activity

In other news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The disclosure for this sale can be found here. Insiders sold a total of 35,361 shares of company stock valued at $248,033 over the last three months. Insiders own 2.70% of the company’s stock.

Institutional Trading of Health Catalyst

Hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its holdings in Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP lifted its holdings in Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the last quarter. Perfromance Wealth Partners LLC acquired a new stake in Health Catalyst during the 2nd quarter worth approximately $64,000. Mackenzie Financial Corp bought a new position in Health Catalyst during the 2nd quarter worth $70,000. Finally, EntryPoint Capital LLC bought a new position in Health Catalyst during the 1st quarter worth $98,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.